The results demonstrated that inhibition of SMYD2 by a specific inhibitor enhanced cell sensitivity to cisplatin in non-small cell lung cancer (NSCLC) (Shang and Wei, 2019), suggesting that the combination of SMYD2 inhibitor and cisplatin may be a novel treatment for patients with cisplatin-resistant NSCLC (Shang and Wei, 2019). This evidence concerns the gene SMYD2 and non-small cell lung carcinoma.